Congress Demands FDA Regulate Compounded GLP-1 Peptides

A bipartisan cohort of United States lawmakers sent formal correspondence to the Food and Drug Administration demanding immediate regulatory closure of bulk substance exemptions for compounded peptides. The inquiry focuses on Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which compounding pharmacies currently use to manufacture unlicensed analogues of semaglutide and tirzepatide under active shortage declarations.

The scale of this grey market is measurable. Data from adverse event reporting systems indicate that state poison control centers logged 3,346 calls regarding compounded semaglutide between January 2023 and mid-2024, frequently involving ten-fold dosing errors driven by non-standard syringe concentrations. Many commercial wellness operators continue to bypass clinical trials by marketing these salt formulations—such as semaglutide sodium and semaglutide acetate—directly to self-directed longevity consumers.

If you currently source injectable metabolic peptides outside traditional pharmacy dispensing networks, verify the salt form stated on your vial. A legitimate prescription delivers semaglutide base; any label listing sodium or acetate variants reflects an unapproved research compound lacking bioequivalence verification.